BiondVax Pharmaceuticals Ltd (Nasdaq: BVXV), developer of the universal influenza vaccine candidate M-001, has named Dr Yael Margolin, Adi Raviv, and Samuel Moed as its new directors, it was reported on Tuesday.

Presently, Moed serves as senior vice president, Corporate Strategy at Bristol Myers Squibb (BMS;NYSE: BMY). Earlier he managed strategy for BMS's Worldwide Pharmaceuticals Group. He also led various businesses including as president of US Pharmaceuticals and as president of Worldwide Consumer Healthcare.

Dr Margolin has more than 35 years of experience as senior manager, CEO and board member in venture capital and in the pharmaceutical and biotech industries, leading strategic and business planning, financing, team building, product development and corporate partnerships. From 2005 to 2019, he served as president, chief executive officer and director of Gamida Cell Ltd (Nasdaq: GMDA). Prior to that, Dr Margolin was vice president of Denali Ventures LLC.

Raviv is a senior financial executive with a career spanning more than 30 years. Since April 2016, he has been a principal at Capacity Funding LLC. Prior to that, he served in a chief financial officer position in two other companies that provide similar types of funding alternatives – New Era Lending from May 2015 to March 2016, and Kapitus (formerly, Strategic Funding Source) from 2009 to 2014. He has extensive capital markets, cash management, corporate finance, investor relations, restructuring, tax and treasury, and transactional experience along with knowledge of the private equity and venture capital arenas. He co-founded THCG Inc and has been involved with companies in challenging start-up, growth, and turnaround environments. He has served on the boards of directors of many private and several public companies, as well as various non-profit entities.